Welcome To The Resverlogix HUB On AGORACOM

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial and Will Soon Begin Phase 2a Kidney Dialysis and Phase 1 Fabry Disease Trials**

Free
AGORACOM NEWS FLASH

BREAKING NEWS!!!

Tartisan Resources Corp. to Acquire Canadian Arrow Mines Limited

 

  • Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited by way of a court-approved plan of arrangement
  • Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan

 

Tartisan logo copy

Hub On AGORACOM / Read Release

Message: Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

News Release Issued: Jan 5, 2017 (3:43pm MST)

Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

CALGARY, Jan. 5, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) today announces its participation in the 9th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. Mr. Donald J. McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.

Presentation Details:

Date: January 9th
Time: 2:00pm PT 
Duration: 30 minutes
Location: Room 3 (Ballroom Level) at the Hilton San Francisco Union Square 

Mr. McCaffrey's presentation will be available on the Company website on the Media/Events page immediately prior to the scheduled presentation time. 

To schedule a meeting with senior management in San Francisco during the event, please contact Investor Relations.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). 

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). 

For further information please visit www.resverlogix.com

Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog

For further information please contact:

Investor Relations
Email: 
[email protected]
Phone: 403-254-9252

SOURCE Resverlogix Corp.

Share
New Message
Please login to post a reply